Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause

• Published in: Expert opinion on drug metabolism & toxicology Vol. 12; no. 10; p. 1233
• Main Authors: Bondi, Chiara, Ferrero, Simone, Scala, Carolina, Tafi, Emanuela, Racca, Annalisa, Venturini, Pier Luigi, Leone Roberti Maggiore, Umberto
• Format: Journal Article
• Language: English
• Published: England 02.10.2016
• Subjects: Animals; Dyspareunia - drug therapy; Dyspareunia - pathology; Female; Female Urogenital Diseases - drug therapy; Female Urogenital Diseases - etiology; Female Urogenital Diseases - pathology; Humans; Menopause; Postmenopause; Selective Estrogen Receptor Modulators - pharmacokinetics; Selective Estrogen Receptor Modulators - pharmacology; Selective Estrogen Receptor Modulators - therapeutic use; Syndrome; Tamoxifen - analogs & derivatives; Tamoxifen - pharmacokinetics; Tamoxifen - pharmacology; Tamoxifen - therapeutic use; Atrophy; menopause; genitourinary syndrome; pharmacodynamics; pharmacokinetics; clinical efficacy; dyspareunia; ospemifene

Ospemifene is a selective estrogen receptor modulator recently approved by the FDA for the treatment postmenopausal women experiencing moderate-to-severe dyspareunia and by the EMA for the treatment of moderate-to-severe symptomatic genitourinary syndrome of menopause (GSM) in women who are not suit...